Merck's COX-2 selective nonsteroidal anti-inflammatory drug Vioxx (rofecoxib) was approved for use in the US in 1999 and remained on the market for just five years before being pulled due to concerns that it could raise the risk of heart attack and stroke. By that time, some 80 million people worldwide had taken the drug, primarily to treat osteoarthritis, acute pain, and dysmenorrhea. Before long, the drugmaker found itself facing thousands of lawsuits. How much did it earmark for settlements?
Source: Vioxx Withdrawn from Market Because of Cardiovascular Concerns (2004) (http://encyclopedia.thefreedictionary.com/Vioxx)